cas 202825-46-5 (mesylate)
Newron Pharmaceuticals and fellow Italy-headquartered partner Zambon have filed their investigational Parkinson’s disease treatment safinamide with regulators in the USA.
The submission to the US Food and Drug Administration is for safinamide as add-on therapy in early and mid-to late stage PD patients. Newron said the filing was based on “completion of activities agreed upon during meetings” with the FDA, noting that a marketing authorisation application was submitted to the European Medicines Agency in December.
Safinamide (EMD 1195686) is a candidate drug against Parkinson’s disease with multiple methods of action. In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011. The compound was originally discovered at Farmitalia-Carlo…
View original post 494 more words